CPI 444

Drug Profile

CPI 444

Alternative Names: Adenosine A2A Receptor Antagonist - Corvus; CPI444; Immune checkpoint inhibitor A; V 81444

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Genentech; Vernalis
  • Class Antineoplastics; Antiparkinsonians; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 20 Jul 2017 Phase-I clinical trials in Cancer (In volunteers) in USA (PO) (NCT03237988)
  • 05 Jun 2017 Adverse event and efficacy data from a phase I/Ib trial in Cancer presented at the 53rd American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Updated efficacy and adverse events data from a phase I/Ib trial in Solid tumours, including Renal cell and Non-small cell lung cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top